TYRO3
Tyrosine-protein kinase receptor TYRO3
Also known as: Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif, TYRO3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q06418
- Gene
- TYRO3
- Ensembl
- ENSG00000092445
- Chromosome
- 15
- Canonical length
- 890 aa
- Protein class
- Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The gene is part of a 3-member transmembrane receptor kinase receptor family with a processed pseudogene distal on chromosome 15. The encoded protein is activated by the products of the growth arrest-specific gene 6 and protein S genes and is involved in controlling cell survival and proliferation, spermatogenesis, immunoregulation and phagocytosis. The encoded protein has also been identified as a cell entry factor for Ebola and Marburg viruses. [provided by RefSeq, May 2010]
Canonical amino-acid sequenceUniProt
890 residues, UniProt reviewed canonical sequence.
>Q06418|TYRO3
1 MALRRSMGRP GLPPLPLPPP PRLGLLLAAL ASLLLPESAA AGLKLMGAPV KLTVSQGQPV
61 KLNCSVEGME EPDIQWVKDG AVVQNLDQLY IPVSEQHWIG FLSLKSVERS DAGRYWCQVE
121 DGGETEISQP VWLTVEGVPF FTVEPKDLAV PPNAPFQLSC EAVGPPEPVT IVWWRGTTKI
181 GGPAPSPSVL NVTGVTQSTM FSCEAHNLKG LASSRTATVH LQALPAAPFN ITVTKLSSSN
241 ASVAWMPGAD GRALLQSCTV QVTQAPGGWE VLAVVVPVPP FTCLLRDLVP ATNYSLRVRC
301 ANALGPSPYA DWVPFQTKGL APASAPQNLH AIRTDSGLIL EWEEVIPEAP LEGPLGPYKL
361 SWVQDNGTQD ELTVEGTRAN LTGWDPQKDL IVRVCVSNAV GCGPWSQPLV VSSHDRAGQQ
421 GPPHSRTSWV PVVLGVLTAL VTAAALALIL LRKRRKETRF GQAFDSVMAR GEPAVHFRAA
481 RSFNRERPER IEATLDSLGI SDELKEKLED VLIPEQQFTL GRMLGKGEFG SVREAQLKQE
541 DGSFVKVAVK MLKADIIASS DIEEFLREAA CMKEFDHPHV AKLVGVSLRS RAKGRLPIPM
601 VILPFMKHGD LHAFLLASRI GENPFNLPLQ TLIRFMVDIA CGMEYLSSRN FIHRDLAARN
661 CMLAEDMTVC VADFGLSRKI YSGDYYRQGC ASKLPVKWLA LESLADNLYT VQSDVWAFGV
721 TMWEIMTRGQ TPYAGIENAE IYNYLIGGNR LKQPPECMED VYDLMYQCWS ADPKQRPSFT
781 CLRMELENIL GQLSVLSASQ DPLYINIERA EEPTAGGSLE LPGRDQPYSG AGDGSGMGAV
841 GGTPSDCRYI LTPGGLAEQP GQAEHQPESP LNETQRLLLL QQGLLPHSSCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TYRO3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 44 nTPM
Expression across tissuesHPA
Tissue
- ovary: 44 nTPM
- cerebral cortex: 38 nTPM
- cerebellum: 33 nTPM
- spinal cord: 28 nTPM
- adipose tissue: 20 nTPM
- testis: 18 nTPM
Single-cell type
- podocytes: 443 nCPM
- sertoli cells: 101 nCPM
- oligodendrocytes: 77 nCPM
- leydig cells: 77 nCPM
- peritubular myoid cells: 68 nCPM
- granulosa cells: 62 nCPM
Immune cell
- neutrophil: 1.2 nTPM
- basophil: 1 nTPM
- naive B-cell: 0.3 nTPM
- NK-cell: 0.3 nTPM
- plasmacytoid DC: 0.3 nTPM
- classical monocyte: 0.2 nTPM
Brain region
- white matter: 89 nTPM
- cerebral cortex: 88 nTPM
- basal ganglia: 75 nTPM
- midbrain: 73 nTPM
- medulla oblongata: 70 nTPM
- amygdala: 63 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.74
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.57
- DepMap mean gene effect
- -0.29
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic cell clearance
- cell adhesion
- cell migration
- cell surface receptor protein tyrosine kinase signaling pathway
- establishment of localization in cell
- forebrain cell migration
- natural killer cell differentiation
- negative regulation of inflammatory response
- negative regulation of innate immune response
- negative regulation of lymphocyte activation
- negative regulation of neuron apoptotic process
- negative regulation of toll-like receptor signaling pathway
- nervous system development
- neuron apoptotic process
- neuron cellular homeostasis
- neuron migration
- neuropeptide signaling pathway
- ovulation cycle
- phagocytosis
- phosphatidylinositol 3-kinase/protein kinase B signal transduction
- platelet activation
- platelet aggregation
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of viral life cycle
- secretion by cell
- signal transduction
- spermatogenesis
- substrate adhesion-dependent cell spreading
- vagina development
Molecular functions
- ATP binding
- phosphatidylinositol 3-kinase binding
- protein tyrosine kinase activity
- transmembrane receptor protein tyrosine kinase activity
- virus receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Protein kinase domain
- Serine-threonine/tyrosine-protein kinase, catalytic domain
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Fibronectin type III
- Immunoglobulin-like domain
- Tyrosine-protein kinase, active site
- Protein kinase-like domain superfamily
- Immunoglobulin I-set
- Immunoglobulin-like fold
- Protein kinase, ATP binding site
- Tyrosine-protein kinase, catalytic domain
- Fibronectin type III superfamily
- Immunoglobulin-like domain superfamily
- Receptor Tyrosine Kinase
- Fibronectin type III domain
- Immunoglobulin I-set domain
- Protein tyrosine and serine/threonine kinase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TYRO3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TYRO3 as an antibody target. Whether an autoantibody or antibody against TYRO3 could matter depends on whether native TYRO3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TYRO3 is annotated at the cell surface, where native TYRO3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TYRO3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...